Objective-Assessment of thrombus inflammation in vivo could provide new insights into deep vein thrombosis (DVT) resolution. Here, we develop and evaluate 2 integrated fluorescence molecular-structural imaging strategies to quantify DVT-related inflammation and architecture and to assess the effect of thrombus inflammation on subsequent DVT resolution in vivo. Methods and Results-Murine DVT were created with topical 5% FeCl 3 application to thigh or jugular veins (n=35). On day 3, mice received macrophage and matrix metalloproteinase activity fluorescence imaging agents. On day 4, integrated assessment of DVT inflammation and architecture was performed using confocal fluorescence intravital microscopy. Day 4 analyses showed robust relationships among in vivo thrombus macrophages, matrix metalloproteinase activity, and fluorescein isothiocyanate-dextran deposition (r>0.70; P<0.01). In a serial 2-time point study, mice with DVT underwent intravital microscopy at day 4 and day 6. Analyses revealed that the intensity of thrombus inflammation at day 4 predicted the magnitude of DVT resolution at day 6 (P<0.05). In a second approach, noninvasive fluorescence molecular tomography-computed tomography was used and detected macrophages within jugular DVT (P<0.05 versus sham controls). 
D
eep vein thrombosis (DVT) occurs in >350 000 patients annually in the United States. 1 In addition to the acute risk of pulmonary embolism, up to 50% of all DVT patients will develop post-thrombotic syndrome (PTS), despite appropriate anticoagulant therapy. 2 PTS symptoms include pain, heaviness, swelling, and cramping in the affected limb, which are frequently aggravated by standing and walking. In advanced cases, extensive varicose vein and acute venous ulcers can form. PTS occurs after incomplete DVT resolution and DVTinduced vein wall and valve damage, leading to venous hypertension, valvular incompetence, and chronic inflammation.
It is now established that venous thrombosis is an inflammatory process, [3] [4] [5] with accumulating evidence demonstrating that inflammation orchestrates DVT resolution. [6] [7] [8] [9] [10] [11] At present, however, minimal data are available regarding in vivo spatiotemporal measures of leukocyte influx and inflammatory mediators and their subsequent effects on DVT resolution. Furthermore, it is not known whether the extent of inflammation can predict the magnitude of subsequent DVT resolution. Therefore, the development and application of in vivo inflammation molecular imaging approaches [12] [13] [14] could provide new insights into DVT resolution and inform the future development of PTS.
In this experimental murine investigation, we harness multispectral and multimodal fluorescence molecular imaging to quantify the in vivo inflammatory response elicited by subacute DVT and then assess the impact of DVT inflammation on subsequent DVT resolution. We first validate and then use multiwavelength intravital microscopy (IVM) to simultaneously assess thrombus macrophages, matrix metalloproteinase (MMP) activity, and thrombus architecture in resolving venous thrombi. We then apply serial, 2-time point IVM to investigate whether the initial intensity of the inflammatory response in FeCl 3 -induced DVT predicts the magnitude of DVT resolution in vivo. In a translational study, we assess whether noninvasive integrated fluorescence molecular tomography (FMT)-computed tomography (CT) can detect inflammatory macrophages in subacute jugular DVT.
Methods
IVM imaging system and image analysis, IVM fluorescein isothiocyanate (FITC)-dextran time-course experiments, histological image analysis, correlative histopathology, and fluorescence microscopy are detailed in the online-only Data Supplement.
Experimental Venous Thrombosis
The Subcommittee on Research Animal Care at Massachusetts General Hospital approved all animal studies. Male C57Bl/6 mice (n=35 total, 26 for thigh IVM studies and 9 for jugular FMT-CT/ fluorescence reflectance imaging [FRI] studies) were obtained from Jackson Laboratory (Bar Harbor, ME) and were 12 to 16 weeks of age at the time of study (Figure 1 ). DVT was created using topical FeCl 3 15,16 to induce vessel wall injury and venous thrombosis in the thigh containing the distal femoral vein and the proximal saphenous vein. At day 0, mice were anesthetized with an intraperitoneal injection of ketamine and xylazine (80/12 mg/kg). For the thigh vein thrombosis model, a midline skin incision was made and vessels were gently exposed by blunt dissection. A 1×2 mm strip of number 1 filter paper (Whatman, Inc) was soaked in 5% FeCl 3 and applied to the anterior surface of the femoral/saphenous vein for 5 minutes. After removal of the filter paper, the area was thoroughly rinsed with sterile saline, and the surgical incision was sutured closed.
A similar procedure was followed to create jugular vein thrombi. After blunt dissection of the jugular vein, a 1-mm-wide strip of filter paper soaked in 7.5% FeCl 3 was placed on the anterior surface of the vein for 3 minutes. The area was then rinsed with sterile saline, and the surgical incision was sutured closed. Sham surgery with topical saline was also performed on the contralateral jugular vein. In all mice, buprenorphine analgesia (0.05-0.1 mg/kg IP) was administered 30 minutes before induction of anesthesia and every 12 hours after procedure.
Fluorescent Imaging Agents
Crosslinked dextran-coated magnetofluorescent nanoparticles were harnessed for imaging of macrophages. 17, 18 Briefly, crosslinked iron oxide (CLIO) nanoparticles were obtained from the Center for Systems Biology Chemistry Core at Massachusetts General Hospital. To 20 mg of CLIO (9.98 mg Fe/mL) was added 1 mg of AlexaFluor 555 (λ max absorption=555 nm, λ max emission=565 nm, AF555, Invitrogen, Carlsbad, CA) or, for FMT studies, 1 mg of VivoTag 680 (λ max absorption=670 nm, λ max emission=688 nm, VT680, PerkinElmer, Waltham, MA) in 200 µL dimethylsulfoxide. The reaction was allowed to proceed for 16 hours, at which time it was filtered through Sephadex G25 to yield the magnetofluorescent nanoparticles (CLIO-AF555, 3.6 mg Fe/mL, 1.8×10 −04 M AF555; CLIO-VT680, 4.7 mg Fe/mL, 1.0×10 −04 M VT680). MMP activity within the thrombus was imaged using a proteaseactiva table near-infrared fluorescence reporter (MMPSense-680, excitation/emission 680/700 nm, PerkinElmer). MMPSense is optically silent upon injection and becomes highly fluorescent after gelatinase MMP-mediated activation. 19, 20 FITC-modified dextran (FITC-dextran, 0.5 mg in 100 μL PBS, λ max absorption=490 nm, λ max emission=520 nm, molecular weight 2 000 000, Sigma Chemical, St. Louis, MO), injected immediately before IVM, enabled vessel angiography and thrombus anatomical imaging. Tetramethylrhodamine-modified dextran (tetramethylrhodamine-dextran, 0.5 mg in 100 μL PBS, λ max absorption=557 nm, λ max emission=576 nm, molecular weight 2 000 000, Sigma Chemical) was also used in IVM validation experiments.
Confocal Fluorescence IVM
For fluorescence IVM studies, n=16 mice were injected on day 3 with the macrophage sensor CLIO-AF555 (10 mg Fe/kg). Twelve of the 16 CLIO-AF555-injected mice were additionally injected with MMPSense-680 (150 nmol/kg) dissolved in sterile PBS. Macrophage and MMP activity agents were injected 24 hours before imaging. Additional uninjected mice with DVT (n=3) served as IVM controls.
All mice were injected with the angiographic agent FITC-dextran as described above. To determine whether FITC-dextran would deposit into thrombi in vivo, a set of serial IVM time-course experiments was performed (see Methods in the online-only Data Supplement).
In the first IVM imaging study, mice underwent IVM once at day 4 (n=16, 10 injected with inflammation imaging agents and Figure 1 . Experimental model of venous thrombosis and study protocol. A, Diagram of mouse femoral/saphenous bundle with example images of vein thrombus induction using 5% FeCl 3 -soaked filter paper. Images shown are at 15 minutes postinduction at day 0, then at day 4, day 6, and after saline perfusion (perfused). B, Study protocol for intravital microscopy and fluorescence molecular tomography-computed tomography (FMT-CT) molecular-structural imaging protocols. Scale bar, 0.5 mm. DVT indicates deep vein thrombosis; CLIO, crosslinked iron oxide; FRI, fluorescence reflectance imaging; FITC, fluorescein isothiocyanate; MMP, matrix metalloproteinase; IVM, intravital microscopy. 6 uninjected), followed by euthanasia and histological assessment. In a second IVM imaging experiment, mice underwent serial IVM once on day 4 and then once on day 6 (n=10, 6 for 2-time point inflammation imaging and 4 for FITC-dextran time-course imaging).
During the IVM procedure, the thigh vessels of anesthetized mice were exposed, and the thrombus region was visually identified in the femoral/saphenous vein. The area was then bathed in sterile saline at room temperature, a coverglass was placed on the vessel surface, and the mouse was placed on the stage of a custom-built laser scanning intravital confocal microscope. 21 See the online-only Data Supplement for details on the IVM imaging system and IVM image analysis methodology.
Fluorescence Reflectance Imaging
To image macroscopic DVT inflammation, n=9 mice with subacute jugular DVT underwent ex vivo FRI studies. At day 3 post-DVT, mice were injected via tail vein with the near-infrared macrophage reporter CLIO-VT680 (10 mg Fe/kg, Massachusetts General Hospital-Center for Systems Biology, n=6) or PBS (n=3). On day 4, mice were euthanized, and both jugular veins were carefully dissected, rinsed in sterile PBS, and placed on the stage of an FRI system (Kodak Image Station 4000MMPro, Carestream Health Inc, New Haven, CT). Optical images at 630/700 nm excitation/emission were collected with 42×42 micron spatial resolution and 8-second exposure time. For these images, the target-to-background ratio (TBR) was calculated as mean thrombus signal/mean sham signal, and therefore represents number-fold change over sham-operated veins.
Fluorescence Molecular TomographyComputed Tomography
Before FRI, the 6 mice that received CLIO-VT680 underwent noninvasive in vivo FMT-CT imaging of jugular DVT on day 4. FMT was performed at 680 nm/700 nm excitation/emission wavelengths with 1-mm isotropic resolution using an FMT 2500 system (PerkinElmer), as previously described. 22 Briefly, anesthetized mice were placed in a multimodal imaging cartridge that allows for coregistration of FMT and CT data through the use of multimodal fiducial markers. FMT imaging took ≈5 to 8 minutes. Immediately after FMT, CT angiography was performed to map the jugular veins (Inveon PET-CT, Siemens). The 3-dimensional CT spatial resolution was 80 μm. To visualize the lumen of jugular veins, mice were continuously infused with the radiopaque contrast agent Isovue-370 (Bracco Diagnostics) at 50 μL/min via the tail vein. CT imaging took ≈10 minutes. Reconstructed FMT and CT images were imported into OsiriX software to coregister and create fusion images. After FMT-CT, resected jugular veins were imaged by ex vivo FRI, as described above.
Statistical Analysis
All results are reported as mean±SD. Correlation coefficients were determined using linear regression and by calculating Pearson correlation coefficient (r). Differences between thrombus area and length at day 4 and day 6 were assessed using the paired Student t test. Differences in thrombus length and area measurements in the FITC-dextran time-course experiments were assessed using ANOVA. A P value <0.05 was considered statistically significant. To assess rate agreement for the IVM measurement of thrombus length, the intraclass correlation coefficient (1-way random effects model) was calculated using IBM SPSS Statistics version 21. All other statistical analyses were performed using Prism (v 5.0c, GraphPad, La Jolla, CA).
Results

In Vivo Assessment of Inflammation in Subacute DVT
Inflammatory macrophages and MMP activity in day 4 murine DVT were visualized via IVM and the spectrally distinct fluorescence imaging reporters CLIO-AF555 and MMPSense-680, respectively. Prior experimental work suggests the day 4 time point as the transition point of polymorphonuclear leukocyte to monocyte/macrophage influx. 3, 23 Vessel angiograms, obtained with FITC-dextran, provided high-resolution images of dark thrombi surrounded by bright luminal signal intensity (Figure 2 ). The average thrombus length was 1.09±0.27 mm. Macrophage and MMP activity IVM signals were detectable to a depth of ≈90 μm from the top of the vessel ( Figure I in the online-only Data Supplement), with heterogeneous signal intensity noted throughout the thrombus. Elevated inflammatory signals were noted often along the thrombus edges (Figures 2 and 3) .
The average macrophage and MMP activity TBR, calculated by encompassing the entire thrombus area, were 2.07±0.51 and 1.21±0.27, respectively. The CLIO-AF555 macrophage signal reflected the signal above the circulating background, which is typically low 24 hours after injection of 10 mg/ kg CLIO. 20 Although the MMP TBR was just slightly >1, it was significantly greater than the TBR of uninjected mice in the 680-nm channel (TBR uninjected, 0.70±0.18; P=0.009), with a TBR <1.0 as a result of stronger light absorbance of thrombi.
Hematoxylin and eosin histopathology of the femoral/ saphenous bundle demonstrated partially occlusive venous thrombi at the site of FeCl 3 treatment in all animals ( Figure  II in the online-only Data Supplement). Fluorescence microscopy of CLIO-AF555 and MMPSense-680 signals corresponded with immunoreactive macrophages and MMP-9, consistent with prior investigations of CLIO 18 and the MMP activity sensor 19, 20 ( Figure 3A and 3B).
In Vivo Relationships Among Inflammation, FITC-Dextran, and Area in Resolving DVT
Substantial topographical heterogeneity of thrombus macrophages and MMP activity were noted along the thrombus length (Figures 2A) . Quantitative IVM analyses revealed that whole-thrombus macrophage and MMP activity associated closely (r=0.84; P=0.001; Figure 4A ). At day 4, measures of whole-thrombus inflammation and FITC-dextran deposition did not correlate with day 4 thrombus area (P>0.05; Figure 4D -4F). Interestingly, 45 minutes after FITC-dextran injection, IVM images demonstrated augmented FITC-dextran signal within thrombus zones, often including thrombus-lumen edge interfaces (Figure 2A) . To further understand whether the FITC signal within thrombi was a result of time-dependent uptake of FITC-dextran (as opposed to pores within the thrombus), a serial IVM time-course experiment was performed. Serial IVM images ( Figure III in the online-only Data Supplement) demonstrated that thrombus regions enhanced over the 60-minute imaging period, with minimal thrombus interior signal noted at the 10-minute time point, in contrast to the 30-, 45-, and 60-minute time points.
In vivo measures of whole-thrombus inflammation (macrophage, MMP activity) were found to significantly associate with in vivo FITC deposition (r=0.75; P=0.001 and r=0.74; P=0.006, respectively; Figure 4B and 4C). This finding further suggested that FITC-dextran was depositing into the thrombus. This observation was confirmed on fluorescence microscopy ( Figure 3C ; Figures IV and V in the online-only Data Supplement).
To further understand mechanisms of FITC-dextran deposition into thrombi in vivo, a line-by-line segmental analysis of thrombus macrophages and FITC-dextran signal was performed across thrombi ( Figure IVA revealed that the FITC-dextran deposited into deeper thrombus zones ( Figure 3C ; Figures IV and V in the online-only Data Supplement), suggesting that diffusion did not exclusively govern FITC-dextran deposition into murine DVT.
Thrombus Inflammation and Subsequent DVT Resolution
To investigate whether the intensity of the DVT-associated inflammatory response could inform the future extent of DVT resolution, we performed a serial IVM 2-time point study in a separate group of mice (n=6). IVM was performed on day 4 for thrombus inflammation and architecture, and then again on day 6 for thrombus architecture. DVT resolution was then evaluated by quantifying the change in thrombus area and thrombus length from day 4 to day 6.
First, to confirm that the above IVM methodology could accurately measure thrombus length and area over both imaging sessions, IVM data from the time-course studies (n=4 mice) and additional mice (n=3) were analyzed. The timecourse studies revealed that thrombus length and area measurements derived from FITC-dextran images were stable over the 60-minute IVM imaging session ( Figure IIID 
P=0.002).
The IVM data demonstrated greater reductions in DVT burden in mice with higher degrees of DVT inflammation at day 4 ( Figures 5 and 6 ). The intensity of the macrophage response (whole-thrombus macrophage TBR) correlated strongly with reductions in thrombus length and area (r=0.92 and r=0.93; Figure 6B and 6E, respectively; P<0.05). The intensity of the MMP activity (wholethrombus MMP activity TBR) also correlated strongly with reductions in thrombus length (r=0.92; Figure 6C ; P<0.05) and showed a trend with reduced thrombus area (r=0.54; Figure 6F ; P>0.05).
Noninvasive FMT-CT Imaging of Thrombus Inflammation
Noninvasive imaging of thrombus macrophages may offer a translational approach to assess inflammation in DVT resolution and the future development of PTS. Therefore, integrated noninvasive FMT-CT 22, 26 was performed on day 4 mice with jugular DVT (Figure 7 ). To enable in vivo noninva sive fluorescence imaging, the CLIO-based macrophage sensor (CLIO-VT680, excitation/emission 670/688 nm) was red-shifted into the near-infrared window. . Serial intravital microscopy micrographs at day 4 and day 6 of 2 deep vein thrombosis subjects. A, In a thrombus with relatively high inflammatory macrophage and matrix metalloproteinase (MMP) activity at day 4, the thrombus length and area were reduced by 37.0% and 50.5%, respectively, from day 4 to day 6. B, In a thrombus with relatively lower inflammatory macrophage and MMP, respectively, the thrombus length and area were reduced by 25.0% and 43.4%, respectively, from day 4 to day 6. Macrophage (MAC, green) and MMP activity (MMP, red) micrographs are overlaid with fluorescein isothiocyanate-dextran angiogram (ANGIO, grayscale). Yellow dashed lines demarcate the measured region of interest of the thrombus at day 4 and day 6. Scale bar, 200 μm. TBR indicates target-to-background ratio. CLIO-VT680 in the DVT was significantly higher in the CLIO-treated group compared with a saline-treated group (CLIO-VT680 group n=6, thrombus TBR=1.65±0.09 versus saline group n=3, thrombus TBR=1.04±0.14, P<0.006; Figure 7B and 7C).
Discussion
In this experimental murine venous thrombosis study, we investigated the in vivo spatiotemporal relationships of inflammatory cells and proteinase factors that mediate DVT resolution. We found that the inflammatory response can predict the extent of DVT resolution in an FeCl 3 DVT model. IVM and FMT, in conjunction with specialized macrophage and MMP activity fluorescent imaging reporters, enabled assessment of the inflammatory response in murine thigh and jugular DVT. Compared with histological studies of DVT resolution, multitarget IVM provided in vivo, whole-thrombus insights into venous thrombus inflammation, architecture, and resolution.
Recruited thrombus macrophages play a pivotal role in mediating DVT resolution.
3 Landmark histological-based experimental studies demonstrated that deficiency of macrophages impaired DVT resolution [8] [9] [10] and that heightened macrophage responses improved DVT resolution. 6, 27, 28 In day 4 FeCl 3 -induced DVT, the present IVM data revealed substantial thrombus infiltration by macrophages that were heterogeneously distributed along the length of the thrombi. Architecturally, the in vivo thrombus resolution process, as measured by macrophage and MMP activity, demonstrated an outward-in pattern (Figures 2, 3, and 5) , from the edges of the thrombus toward the middle, extending prior ex vivo observations. 9 These findings suggest an active interface between perithrombus leukocytes and the thrombus itself. 8, 9 In addition, the developed IVM imaging method shows great potential for evaluating therapies that might increase monocyte entrance into the thrombus to accelerate resolution. 9 Thrombus MMP activity was simultaneously imaged using a spectrally distinct MMP-activatable imaging agent that reports on MMP activity, in particular MMP-9 and MMP-2, in vivo. 19, 20, 29 MMPs, predominantly gelatinases MMP-2 and MMP-9, likely play an important role in thrombus resolution by promoting collagenolysis and neoangiongenesis, fibrinolysis, 30 and facilitating leukocyte influx into thrombi. 31 A robust correlation of whole-thrombus MMP activity and macrophages was found (r=0.84; P=0.001), supporting that macrophages are a predominant source of active gelatinases in day 4 subacute DVT. FITC-dextran, a routine angiographic agent for IVM, was found to deposit into thrombi at time points after 30 minutes of injection. In vivo and histological assessments demonstrated an association of the FITC-dextran signal with macrophages, MMP activity, and vWF+ regions within thrombi. Although vWF staining in thrombi was present, thrombus neovessels were not clearly visible, possibly because of the earlier day 4 time point used here, as opposed to later time points. 9, 25 Additional studies are required to determine whether specific mechanisms are responsible for FITC-dextran deposition into venous thrombi.
To provide new insights into the inflammatory response and subsequent magnitude of DVT resolution, serial IVM of femoral/saphenous DVT was performed in mice at day 4 and day 6 (Figures 5 and 6 ). We found that the intensity of day 4 inflammatory signals significantly predicted the magnitude of the reduction in DVT burden at day 6 (r values, 0.54-0.92). The overall IVM findings provide new in vivo evidence that local macrophage and MMP activity facilitate favorable DVT resolution, presumably by promoting plasminogen activation and fibrinolysis, as well as neoendothelialization and possibly early collagenolysis. 8, 9, 30 In future studies, the developed IVM methodology can be used to evaluate the in vivo effects of inflammation-modulating therapies (genetic and pharmacological) on DVT resolution.
FMT-CT imaging enabled the detection of macrophages in subacute DVT ( Figure 7 ) and thus offers a noninvasive molecular-structural approach to track the DVT inflammatory response. In addition, because the CLIO particle can also serve as a magnetic resonance imaging macrophage imaging agent, 17, 32 noninvasive magnetic resonance imaging of macrophages in DVT may also be possible (magnetic resonance imaging was not used in this study because of confounding signal changes from FeCl 3 ). 33 Because CLIOlike superparamagentic nanoparticles have already been tested in patients, translational extension of this work may enable molecular imaging of inflammation in DVT at 2 time points: early after DVT (<1 month), where impaired inflammation is likely to identify poorly resolving thrombi and therefore patients at risk for PTS, 34 and later after DVT (>3 months), where persistent inflammation indicates a high risk for PTS. 35, 36 Limitations are present in this study. Later time points beyond day 6 DVT were not amenable to IVM because of superficial scar formation induced by FeCl 3 , which limited light penetration and thus IVM assessment of deeper vessels. Alternative murine thrombosis models such as ligation with venous stasis may overcome this limitation and be more clinically relevant but require greater technical development in the smaller femoral/saphenous vessels. Because thrombi extended deeper than 100 μm, confocal IVM did not permit full thrombus volume measurement; multiphoton IVM approaches may allow deeper imaging. Regarding delivery of the imaging agents to the thrombus, if restricted diffusion (ie, limited thrombus permeability) is present, it is possible that the CLIO and MMP signals may not reflect the full extent of macrophages and MMP activity, respectively, within the thrombus. Of note, MMP activity, although beneficial for thrombus resolution, may detrimentally affect the vein wall. 37 The ability to resolve the vein wall from the thrombus was not feasible in the current IVM confocal imaging study but may become feasible using higher-resolution multiphoton imaging approaches coupled with motion compensation methods.
